| Michael Eugene Shapiro, MD | |
|
1285 Nininger Rd, Hastings, MN 55033-1086 | |
| (651) 480-4200 | |
| (651) 480-4306 |
| Full Name | Michael Eugene Shapiro |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 1285 Nininger Rd, Hastings, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043717622 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 74265 (Minnesota) | Primary |
| Entity Name | St Josephs Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568415974 PECOS PAC ID: 8224948443 Enrollment ID: O20031119000468 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
The Indian Council of Social Science Research (ICSSR) in association with the Deutsche For-schungsgemeinschaft (DFG, German Research Foundation), the French Agence Nationale de la Recherche (ANR), the UKEconomic and Social Research Council (ESRC), the Netherlands Organi-sation for Scientific Research (NWO) have launched the first set of projects for networking and social science research cooperation between researchers in India and the four European countries.
After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.
Researchers at UT Southwestern Medical Center have found an "Achilles heel" in a metabolic pathway crucial to stopping the growth of lung cancer cells.
› Verified 3 days ago
| Entity Name | Minnesota Urology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912971912 PECOS PAC ID: 0840183984 Enrollment ID: O20040204000003 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
The Indian Council of Social Science Research (ICSSR) in association with the Deutsche For-schungsgemeinschaft (DFG, German Research Foundation), the French Agence Nationale de la Recherche (ANR), the UKEconomic and Social Research Council (ESRC), the Netherlands Organi-sation for Scientific Research (NWO) have launched the first set of projects for networking and social science research cooperation between researchers in India and the four European countries.
After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.
Researchers at UT Southwestern Medical Center have found an "Achilles heel" in a metabolic pathway crucial to stopping the growth of lung cancer cells.
› Verified 3 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
The Indian Council of Social Science Research (ICSSR) in association with the Deutsche For-schungsgemeinschaft (DFG, German Research Foundation), the French Agence Nationale de la Recherche (ANR), the UKEconomic and Social Research Council (ESRC), the Netherlands Organi-sation for Scientific Research (NWO) have launched the first set of projects for networking and social science research cooperation between researchers in India and the four European countries.
After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.
Researchers at UT Southwestern Medical Center have found an "Achilles heel" in a metabolic pathway crucial to stopping the growth of lung cancer cells.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Eugene Shapiro, MD 2925 Chicago Ave, Minneapolis, MN 55407-1321 Ph: (612) 262-9000 | Michael Eugene Shapiro, MD 1285 Nininger Rd, Hastings, MN 55033-1086 Ph: (651) 480-4200 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
The Indian Council of Social Science Research (ICSSR) in association with the Deutsche For-schungsgemeinschaft (DFG, German Research Foundation), the French Agence Nationale de la Recherche (ANR), the UKEconomic and Social Research Council (ESRC), the Netherlands Organi-sation for Scientific Research (NWO) have launched the first set of projects for networking and social science research cooperation between researchers in India and the four European countries.
After beginning treatment with remdesivir for COVID-19, a patient experienced significant bradycardia, or low heart rate. Her physicians used a dopamine infusion to stabilize her through the five-day course of remdesivir treatment, and her cardiac condition resolved itself at the end of the treatment.
Researchers at UT Southwestern Medical Center have found an "Achilles heel" in a metabolic pathway crucial to stopping the growth of lung cancer cells.
› Verified 3 days ago